Helmholtz Diabetes Center
Institute for Diabetes Research and Metabolic Diseases
The primary research goal of the Institute for Diabetes Research and Metabolic Diseases (IDM) is the individualized prediction of diabetes risk and diabetes prevention and its personalized therapy.
The primary research goal of the Institute for Diabetes Research and Metabolic Diseases (IDM) is the individualized prediction of diabetes risk and diabetes prevention and its personalized therapy.
Director of the Institute of Diabetes Research and Metabolic Diseases (IDM) Helmholtz Munich at the University Hospital Tübingen
View profile
Group Leader, Scientist
Publications
Birkenfeld, A.L. ; Perreault, L. ; Schmidt, M.I. ; Schwarz, P.E.H. ; Zoungas, S. ; Gong, Q. ; Chan, J.C.N. ; Mohan, V. ; Tuomilehto, J. ; Bergman, M.
Defining prediabetes remission as a distinct prevention endpoint.Vazquez Arreola, E. ; Gong, Q. ; Hanson, R.L. ; Wang, J. ; Sandforth, L. ; He, S. ; Sandforth, A. ; Qian, X. ; Giacca, M. ; Bornstein, S.R. ; Fritsche, A. ; Stefan, N. ; Preissl, H. ; Gregg, E.W. ; Marx, N. ; Jumpertz von Schwartzenberg, R. ; Li, G. ; Birkenfeld, A.L.
Prediabetes remission and cardiovascular morbidity and mortality: Post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study.Wang, Y. ; Ram, J. ; Bianchi, C. ; Fiorentino, T.V. ; Kim, S.S. ; Kim, J. ; Ryang, S. ; Del Prato, S. ; Sesti, G. ; Sandforth, L. ; Preissl, H. ; Jumpertz von Schwartzenberg, R. ; Stefan, N. ; Fritsche, A. ; Ha, J. ; Birkenfeld, A.L. ; Bergman, M.
Superiority of 1 h plasma glucose vs fasting plasma glucose, 2 h plasma glucose and HbA1c for the diagnosis of type 2 diabetes.Mann, J.F.E. ; Marx, N. ; Deanfield, J.E. ; Emerson, S.S. ; Inzucchi, S.E. ; McGuire, D.K. ; Mulvagh, S.L. ; Pop-Busui, R. ; Poulter, N.R. ; Engelmann, M.D.M. ; Hovingh, G.K. ; Belmar, N. ; Idorn, T. ; Jeppesen, O.K. ; Birkenfeld, A.L. ; Amod, A. ; Mankovsky, B. ; Desouza, C. ; Gorgojo-Martinez, J.J. ; Arechavaleta, R. ; Tu, S.T. ; Buse, J.B.
Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: Results from the SOUL randomized trial.Sehgal, R. ; Haacke, N. ; Maguolo, A. ; Solari, F.A. ; Jähnert, M. ; Gottmann, P. ; Nilsson, E. ; Vaag, A. ; Fischer-Posovszky, P. ; Werberger, A. ; Birkenfeld, A.L. ; Fritsche, A. ; Häring, H.-U. ; Sickmann, A. ; Vogel, H. ; Ling, C. ; Ouni, M. ; Schürmann, A.
Adipose tissue-derived microRNAs as epigenetic modulators of type 2 diabetes.Tao, R. ; Stöhr, O. ; Tok, O. ; Andres-Hernando, A. ; Qiu, W. ; He, B. ; Wang, C. ; Grøntved, L. ; Burant, C.F. ; Hui, S.T. ; Lanaspa, M.A. ; Stefan, N. ; Copps, K.D. ; White, M.F.
Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance.Tilg, H. ; Petta, S. ; Stefan, N. ; Targher, G.
Metabolic dysfunction-associated steatotic liver disease in adults: A review.Wang, Y. ; Sandforth, A. ; Jumpertz von Schwartzenberg, R. ; Ganslmeier, M. ; Cheng, Y. ; Sandforth, L. ; Katzenstein, S. ; Machann, J. ; Schick, F. ; Kantartzis, K. ; Preissl, H. ; Fritsche, A. ; Stefan, N. ; Bergman, M. ; Birkenfeld, A.L.
Lifestyle intervention is more effective in high 1-hour post-load glucose than in prediabetes for restoring β-cell function, reducing ectopic fat, and preventing type 2 diabetes.Grieger, J.A. ; Takele, W.W. ; Vesco, K.K. ; Redman, L.M. ; Hannah, W. ; Bonham, M.P. ; Chen, M. ; Chivers, S.C. ; Fawcett, A.J. ; Habibi, N. ; Liu, K. ; Mekonnen, E.G. ; Pathirana, M. ; Quinteros, A. ; Taylor, R. ; Ukke, G.G. ; Zhou, S.J. ; ADA/EASD PMDI (Stefan, N.)
Participant characteristics in the effectiveness of lifestyle interventions to optimize gestational weight gain: A systematic review and meta-analysis.Zhao, S. ; Semeia, L. ; Veit, R. ; Moser, J. ; Preissl, H. ; Kullmann, S.
Structural and functional brain changes in children and adolescents with obesity.
Contact
